Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06552442
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-07-10
Brief Title:
Intracoronary Administration of Glucocorticoids as a Treatment Method for No-Glucocorticoid Treatment for No-Reflow in STEMI
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Intracoronary Administration of Glucocorticoids as a Treatment Method for No-Reflow Phenomenon in STEMI Patients
Status:
COMPLETED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GCT-NR-STEMI
Brief Summary:
The goal of this clinical trial is to improve reperfusion therapy in STEMI patients with no-reflow phenomenon Based on literature review and pathological studies the investigators believe that myocardial ischemia-reperfusion injury is primarily due to myocardial edema which is angiographically manifested by the no-reflow To restore blood flow high-dose intracoronary methylprednisolone was applied The main idea is to stabilize cell membranes and stop the progression of edema It is local not systemic single administration that avoids serious side effects The primary hypothesis is that hormone administration will improve blood flow to TIMI 23 in TIMI 01after stenting infarct-related artery
Detailed Description:
The study involves comparing the main group receiving intracoronary methylprednisolone with a group of patients without intracoronary pharmacotherapy Preliminary results the use of methylprednisolone allows for the restoration of coronary blood flow but does not affect mortality
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None